Samsung Biologics Co.,Ltd.
207940
주식 순위
#496
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
주가
$1,028.49
시가총액
$47.88B
변동 (1일)
-3.67%
변동 (1년)
-18.37%
국가
KR
거래 Samsung Biologics Co.,Ltd. (207940)
카테고리
Healthcare
Samsung Biologics Co.,Ltd. (207940)의 수익
2026 기준 수익 TTM: 0
Samsung Biologics Co.,Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Samsung Biologics Co.,Ltd.의 수익 기록 (2014 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2025 | $1.47B | 55.69% |
| 2024 | $941.97M | 8.88% |
| 2023 | $865.17M | 8.20% |
| 2022 | $799.60M | 69.37% |
| 2021 | $472.11M | 92.69% |
| 2020 | $245.01M | 82.02% |
| 2019 | $134.61M | -50.53% |
| 2018 | $272.09M | -350.00% |
| 2017 | $-108.84M | -43.17% |
| 2016 | $-191.50M | -109.05% |
| 2015 | $2.12B | -2,423.97% |
| 2014 | $-91.10M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $3.01B | - |
BE
|
|
| $1.95B | - |
NL
|
